Buprenorphine/naloxone reduces the reinforcing and subjective effects of heroin in heroin-dependent volunteers.
about
Medications development for opioid abuseMethadone vs. buprenorphine/naloxone during early opioid substitution treatment: a naturalistic comparison of cognitive performance relative to healthy controls.Predictors of buprenorphine-naloxone dosing in a 12-week treatment trial for opioid-dependent youth: secondary analyses from a NIDA Clinical Trials Network study.Impact of research network participation on the adoption of buprenorphine for substance abuse treatment.Human sex differences in d-amphetamine self-administration.Human behavioral pharmacology, past, present, and future: symposium presented at the 50th annual meeting of the Behavioral Pharmacology Society.Sustained release d-amphetamine reduces cocaine but not 'speedball'-seeking in buprenorphine-maintained volunteers: a test of dual-agonist pharmacotherapy for cocaine/heroin polydrug abusersThe drug effects questionnaire: psychometric support across three drug typesBuprenorphine maintenance and mu-opioid receptor availability in the treatment of opioid use disorder: implications for clinical use and policy.The reinforcing, subject-rated, performance, and cardiovascular effects of d-amphetamine: influence of sensation-seeking status.Acute d-amphetamine pretreatment does not alter stimulant self-administration in humansEvaluation of the reinforcing and subjective effects of heroin in combination with dextromethorphan and quinidineTreating Opioid Dependence with Buprenorphine in the Safety Net: Critical Learning from Clinical Data.Naloxone treatment in opioid addiction: the risks and benefits.Controversies in translational research: drug self-administration.The role of human drug self-administration procedures in the development of medications.Clinician beliefs and attitudes about buprenorphine/naloxone diversionSelf-administration of cocaine, cannabis and heroin in the human laboratory: benefits and pitfalls.Intranasal oxycodone self-administration in non-dependent opioid abusers.Effect of Buprenorphine Weekly Depot (CAM2038) and Hydromorphone Blockade in Individuals With Opioid Use Disorder: A Randomized Clinical Trial.Pharmacotherapies for decreasing maladaptive choice in drug addiction: Targeting the behavior and the drug.Does the implementation of evidence-based and culturally competent practices reduce disparities in addiction treatment outcomes?The effects of heroin administration and drug cues on impulsivity.Use of microdoses for induction of buprenorphine treatment with overlapping full opioid agonist use: the Bernese methodClinical models of decision making in addiction.
P2860
Q26853370-FAE261EA-B81A-4A50-8FC6-14F24052BB87Q33287489-E1ED75D5-EBAB-4383-93C4-BAE7D3D17996Q33653252-D302C710-3B10-4086-81C7-E35FCA739E8AQ33776944-49A1D972-93CB-4A08-BC60-D22080196649Q33801853-3F31FB0C-1989-4714-B733-B3AD795113A7Q34033200-13E92EB2-45BD-44F1-A795-D0B6A72FDC3AQ34300251-FE034283-2F09-43E3-9DA2-D30748549631Q34319831-55C0BA9E-0CC8-45D4-AF73-D00D34748BA9Q34615753-81BDACCC-CD0D-4BF5-8F32-CFBD03FBBE7DQ35327605-E8A95234-5691-41D5-8C42-8C90A701AC57Q36099635-8882A23A-6059-46C6-A21C-6DB2F6019A97Q36100597-A786E363-3809-4D93-ADEF-4AFA7CE8F279Q36367544-F5E3CE9B-E007-4F43-A87C-D809601AABCCQ36762428-F812847B-86D7-4D41-8BE7-08B0C634199CQ37087986-532D53EB-3BDC-4ED5-83C4-A6A7F5F5A421Q37147515-EA37A000-FF90-4DC6-BE1C-ACBE7E36C9BEQ37241381-AAB96CCB-6864-4E72-9A30-C5A9B86CE61DQ37294513-F43C807F-AC1E-4D09-8D83-802126A1DE33Q37391604-243C7B84-C187-4D1B-879E-8ED1DC622440Q38374886-41CDD5C4-215A-4C8E-B841-245B7BFD4CECQ38664308-E8F817DB-48CE-4C17-B105-902371CC11F7Q38787669-55D81164-DBE6-4B21-A1DE-94FD03D1B35AQ42362398-62AC93B3-4DB4-4DC5-A3AB-A18D7458752BQ42406269-21072B91-226F-414D-BF23-B61B95BF0358Q45066213-76F0A443-04AA-4E30-8444-F3916C2F6047
P2860
Buprenorphine/naloxone reduces the reinforcing and subjective effects of heroin in heroin-dependent volunteers.
description
2005 nî lūn-bûn
@nan
2005 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Buprenorphine/naloxone reduces ...... n heroin-dependent volunteers.
@ast
Buprenorphine/naloxone reduces ...... n heroin-dependent volunteers.
@en
type
label
Buprenorphine/naloxone reduces ...... n heroin-dependent volunteers.
@ast
Buprenorphine/naloxone reduces ...... n heroin-dependent volunteers.
@en
prefLabel
Buprenorphine/naloxone reduces ...... n heroin-dependent volunteers.
@ast
Buprenorphine/naloxone reduces ...... n heroin-dependent volunteers.
@en
P2093
P2860
P1433
P1476
Buprenorphine/naloxone reduces ...... n heroin-dependent volunteers.
@en
P2093
Ellen A Walker
Eric D Collins
Sandra D Comer
P2860
P2888
P304
P356
10.1007/S00213-005-0023-6
P577
2005-09-29T00:00:00Z
P5875
P6179
1002319959